A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- BioNTech SE
- 入组人数
- 880
- 试验地点
- 85
- 主要终点
- Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant
研究概览
简要总结
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC).
This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).
The main goals of this study are:
- To find the best dose levels (DLs) for the combination of BNT326 and pumitamig.
- To look at how well participants with advanced NSCLC tolerate the combination therapy (for example, which side effects participants experience and how severe they are).
- To look at how well the combination therapy works to shrink the tumor in participants with advanced NSCLC.
详细描述
Part 1 is a combination dose finding part. Participants will receive one of six combination DLs to evaluate and establish safe combination DLs of BNT326 with pumitamig, and to define the recommended Phase 2 combination dose.
Part 2a is a dose expansion part to evaluate the preliminary efficacy, safety, and tolerability.
Part 2b is a randomized dose optimization and contribution of components part.
Parts 1, Part 2a (Cohort A) and Part 2b (Cohort C) will enroll participants with previous exposure to therapy for advanced/metastatic disease. Part 2a (Cohort B) and Part 2b (Cohort D) will enroll participants without prior systemic treatment for advanced/metastatic disease.
The sponsor, having heard the internal review committee (IRC), will determine the DLs for each arm in Part 2b Cohorts C and D based on data generated from Parts 1 and 2a. The DLs chosen for Part 2b Cohorts C and D will not exceed the highest dose level investigated in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(applicable to all participants and all parts unless otherwise specified):
- •Aged ≥18 years at the time of giving informed consent. Local laws will be followed if the age of consent is older.
- •Have measurable disease defined by RECIST v1.
- •Have Eastern Cooperative Oncology Group performance status of 0 or
- •Have adequate organ and bone marrow function within 7 days before randomization/enrollment as defined in the protocol.
- •Have advanced (i.e., metastatic or locally recurrent where local therapy with curative intent is not possible) non-squamous or squamous NSCLC.
- •Cohort-specific inclusion criteria
- •Part 1, 2L+, squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1 (NOTE: regimens used as neoadjuvant and/or adjuvant treatment may be considered as prior lines for advanced disease if relapse occurred within 6 months of the last dose.)
- •for AGA-negative NSCLC only:
- •Have no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, or other genomic alterations for which targeted molecular therapies are available.
- •Have experienced relapse or progression during or after treatment with standard systemic therapy in the advanced/metastatic setting or discontinued from prior therapy due to intolerance.
- •Participants must have received 1 to 3 lines of systemic treatment in the metastatic setting, which can include anti-PD-1/PD-L1 therapy, chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently or sequentially. However, prior chemotherapy treatment must be limited to 2 lines or less.
- •for AGA-positive NSCLC only (excluding EGFR activating mutation):
- •Have documented positive test results for one or more actionable genomic alteration: EGFR (other than activating mutations), ALK, ROS proto-oncogene 1 (ROS1), gene encoding the hepatocyte growth factor receptor (MET), human gene that encodes a protein called B-Raf (BRAF), rearranged during transfection (RET), neurotrophic tropomyosin-receptor kinase (NTRK), human epidermal growth factor receptor 2 (HER2), Kirsten rat sarcoma virus (KRAS), or other genomic alteration with available targeted therapy.
- •Must have received at least one prior systemic therapy for advanced disease, which must have included targeted treatment for actionable genomic alterations, which include alterations such as EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other alterations for which targeted therapies are available as a part of local SoC.
- •Participants may have received between 1 to 3 lines of systemic treatment of anti-PD-1/PD-L1 therapy, chemotherapy, and/or anti-angiogenic agents. These treatments may be administered concurrently (including with tyrosine kinase inhibitor [TKI]) or sequentially. However, chemotherapy treatment must be limited to 2 lines or less.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- •for AGA-positive NSCLC only (with EGFR activating mutation):
- •Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).
- •Participants must have received one or two prior lines of systemic therapy for advanced and/or metastatic disease, which must include treatment with an approved EGFR TKI, with at least one being a third-generation EGFR TKI.
- •Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day
- •Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced/metastatic disease.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- •Part 2a (Cohort A), 2L+, squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1 (NOTE: regimens used as neoadjuvant and/or adjuvant treatment may be considered as prior lines for advanced disease if relapse occurred within 6 months of the last dose.)
- •for AGA-positive NSCLC only, excluding EGFR activating mutation:
- •Have documented positive test results for one or more actionable genomic alterations: EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other genomic alterations, with available targeted therapy.
- •May have received 1 to 4 lines of systemic treatment, of which one prior systemic therapy for advanced disease must have included targeted treatment for actionable genomic alterations, which include alterations such as EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other genomic alterations for which targeted therapies are available as part of local SoC.
- •Other therapies may include anti-PD-1/PD-L1 therapy, chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently/in combination (including with TKI) or sequentially. However, chemotherapy treatment must be limited to 2 lines or less.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- •for AGA-positive NSCLC only, with EGFR activation mutation:
- •Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).
- •Participants must have received one or two prior lines of systemic therapy for advanced and/or metastatic disease, which must include treatment with an approved EGFR TKI, with at least one being a third-generation EGFR TKI.
- •Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day
- •Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced/metastatic disease.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- •Part 2a (Cohort B), 1L, squamous or non-squamous NSCLC, AGA-negative, any PD-L1
- •Have no actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or other genomic alterations for which targeted molecular therapies are available.
- •Have received no systemic anti-cancer treatment in the advanced/metastatic setting. May have received neoadjuvant and/or adjuvant treatment if progression to advanced/metastatic disease occurred at least 6 months after completing such therapy and have not received treatment in the advanced/metastatic setting.
- •Part 2b (Cohort C), 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1
- •for AGA-negative NSCLC only:
- •Have no actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or other genomic alterations for which targeted molecular therapies are available.
- •Participants should have received 1 to 4 lines of systemic treatment, which can include anti-PD-1/PD-L1 therapy, chemotherapy, and/or anti-angiogenic agents.
- •Regimens used as neoadjuvant and/or adjuvant treatment may be considered as prior lines for advanced disease if relapse occurred within 6 months of the last dose.
- •for EGFR-sensitizing mutation NSCLC only:
- •Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).
- •Have received 1 or 2 prior systemic therapies for advanced and/or metastatic disease with an approved EGFR TKI, which must include one third-generation anti-EGFR TKI.
- •Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day
- •Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced/metastatic disease.
- •May have received neoadjuvant and/or adjuvant treatment if progression to advanced/metastatic disease occurred at least 6 months after completing such therapy and have experienced disease progression on or after EGFR TKI treatment administered in the advanced/metastatic setting.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- 另有 3 项未显示
排除标准
- •(applicable to all participants and all parts):
- •Had disease progression on or were intolerant to prior treatment with an agent targeting HER3 (including antibody, ADC, cell therapy, and other drugs) or with a topoisomerase I inhibitor payload (including topoisomerase I inhibitor-containing ADCs). Note: For Part 2a Cohort A, prior exposure to agents targeting HER3 or topoisomerase I inhibitor payload may be allowed on a case-by-case basis after discussion with and approval by the sponsor.
- •Have an uncontrolled concomitant or intercurrent illness, that contra-indicates study participation, limits compliance with study procedures or substantially increases the risk of incurring AEs, including:
- •Bleeding diathesis or active hemorrhage
- •Clinically significant active infection, including respiratory viral infection
- •Child-Pugh class B or C cirrhosis
- •Known pulmonary disease with significant impact in lung function and/or with potential risk of severe infection
- •Oncologic emergencies or complications (e.g., malignant hypercalcemia, superior vena cava syndrome, carcinoid syndrome that is unstable and with available alternative therapies)
- •Psychiatric or abuse condition
- •Infectious colitis Grade ≥2 not resolved to Grade 1 within 72 h within the past 3 months
- •Have left ventricular ejection fraction <50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment.
- •Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment.
- •Have a history of (non-infectious) interstitial lung disease (ILD) /pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.
- •Have had exposure to protocol-specific treatments with a washout period before randomization/enrollment.
- •Have clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- •Are participants of childbearing potential who are pregnant or breastfeeding or are planning pregnancy within the time specified in the protocol or are potentially fertile males, who are planning to father children during the study or within the time specified in the protocol.
- •Are subject to exclusion periods from another investigational study.
- •Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP.
- •Have urine protein ≥2+ and 24-hour urine protein excretion ≥1 g. If qualitative urine protein is ≤1+, a 24-hour urine protein quantitative test is not required.
- •Have a history of Grade ≥3 immune-related adverse events that led to treatment discontinuation of a prior checkpoint inhibitor.
- •Have a significant risk of hemorrhage (per investigator clinical judgment) indicated by protocol defined criteria.
- •Have active or chronic clinically significant corneal disorders or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
- •NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
研究组 & 干预措施
Part 1 - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig, starting dose. In participants with second-line (or higher) 2L(+), squamous or non-squamous NSCLC, actionable genomic alterations (AGA)-negative/positive, any programmed death-ligand 1 (PD-L1).
干预措施: BNT326 (Drug)
Part 2a (Cohort A, Arm 3) - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 1 - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 2) - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2b (Cohort C, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or epithelial growth factor receptor (EGFR) activating mutation, any PD-L1.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
Part 1 - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig, starting dose. In participants with second-line (or higher) 2L(+), squamous or non-squamous NSCLC, actionable genomic alterations (AGA)-negative/positive, any programmed death-ligand 1 (PD-L1).
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 2) - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 1 - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 1) - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 4) - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 5) - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 6) - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort B, Arm 1) - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with first-line (1L) squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 6) - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 2) - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort B, Arm 3) - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort B, Arm 4) - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort B, Arm 5) - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2a (Cohort B, Arm 6) - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: Pumitamig (Drug)
Part 2b (Cohort C, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or epithelial growth factor receptor (EGFR) activating mutation, any PD-L1.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort C, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort C, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
Part 2b (Cohort D1, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort D1, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort D1, Arm 3) - Pumitamig monotherapy
Pumitamig monotherapy. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.
DL used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort D2, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 <50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2b (Cohort D1, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
Part 2b (Cohort D2, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 <50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: Pumitamig (Drug)
Part 2a (Cohort A, Arm 3) - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort A, Arm 5) - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2b (Cohort D2, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 <50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
Part 2a (Cohort A, Arm 4) - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 1 - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 1 - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 1 - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort A, Arm 1) - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort A, Arm 2) - BNT326 (DL2) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 1) - BNT326 (DL1) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with first-line (1L) squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 3) - BNT326 (DL3) + pumitamig (DL1)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 4) - BNT326 (DL1) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 5) - BNT326 (DL2) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2a (Cohort B, Arm 6) - BNT326 (DL3) + pumitamig (DL2)
Combination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
干预措施: BNT326 (Drug)
Part 2b (Cohort D1, Arm 1) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
Part 2b (Cohort D2, Arm 2) - BNT326 + pumitamig
Combination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 <50%.
DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
干预措施: BNT326 (Drug)
结局指标
主要结局
Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant
时间窗: 21 days starting on Day 1 of Cycle 1
During the DLT evaluation period by dose level
Part 1 and Part 2a - Occurrence of treatment emergent adverse events (TEAEs), treatment-related adverse events (TRAE), treatment emergent serious adverse events (TESAE), treatment-related serious adverse events (TRSAE)
时间窗: from the first dose of investigational medicinal product (IMP) up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Part 1 and Part 2a - Occurrence of dose interruption, reduction, and discontinuation due to TEAEs
时间窗: from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Part 2a and Part 2b - Objective response rate (ORR)
时间窗: from the time of initiation of the first dose of IMP to approximately 36 months
Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response.
次要结局
- All cohorts - Pharmacokinetics (PK) assessment: Maximum concentration derived from serum concentrations of BNT326 antibody-drug conjugate (ADC), total anti-human epidermal growth factor receptor 3 (HER3) antibody component, and unconjugated payload(from the first IMP up to safety follow-up, approximately 90 days post last IMP dose)
- Part 1 - ORR(from the time of initiation of the first dose of IMP to approximately 36 months)
- Part 2b - Occurrence of TEAEs, TRAEs, TESAEs, TRSAEs(from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months))
- Part 2b - Occurrence of dose interruption, reduction, and discontinuation due to TEAEs(from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months))
- Part 2a and Part 2b - Progression free survival based on the investigator's assessment(from the first dose of IMP to approximately 36 months)
- Part 2a and Part 2b - Disease control rate(from the first dose of IMP to approximately 36 months)
- Part 2a and Part 2b - Duration of response(from the first dose of IMP to approximately 36 months)
- Part 2a and Part 2b - Time to response(from the first dose of IMP to approximately 36 months)
- Part 2a and Part 2b - Overall survival(from the first dose of IMP to approximately 36 months)
- All cohorts - PK assessment: Time to reach maximum (peak) serum concentration derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the first dose of IMP up to safety follow-up, approximately 90 days post last IMP dose)
- All cohorts - Anti-drug antibody (ADA) prevalence and ADA incidence(up to 1 year from the last dose of IMP)